Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Bo, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734251/
https://www.ncbi.nlm.nih.gov/pubmed/31500657
http://dx.doi.org/10.1186/s13045-019-0786-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734251/
https://www.ncbi.nlm.nih.gov/pubmed/31500657
http://dx.doi.org/10.1186/s13045-019-0786-6

Ejemplares similares